logo

Shariah compliance overview

Halal

Travere Therapeutics, Inc. (TVTX) is currently classified as Halal by Akinda Shariah screening (AAOIFI-aligned methodology).

About Travere Therapeutics, Inc.

Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II).

Travere Therapeutics, Inc. (TVTX) operates in the Healthcare sector, in the Biotechnology industry.

Why it is halal: it passes all three AAOIFI screens. Non-compliant revenue is 2.53% (limit 5%), interest-bearing debt is 14.10% (limit 30%) and interest-bearing securities and assets are 14.60% (limit 30%).

If you hold TVTX, give 2.53% of the dividends you receive to charity to purify the non-compliant share of its income.

Business Activity
2.53%Limit 5%Pass
Interest-bearing debt
14.10%Limit 30%Pass
Interest-bearing securities and assets
14.60%Limit 30%Pass
Dividend purification
2.53%Share of dividends to give to charityPurification calculator

Last updated: Nov 3, 2026 · Screening is informational and not a fatwa. Consult a qualified scholar for personal guidance.

Please login to access this content

Key stats

Please login to access this content

Please login to access this content

Company Profile

Please login to access this content

Frequently asked questions

Quick answers about Travere Therapeutics, Inc. (TVTX). Current Akinda screening label: Halal.